BridgeBio Pharma stock
Price history
+20.35% over the period1 year: from $65.06 (November 13, 2025) to $78.30 (November 13, 2026), +20.35%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $78.30 |
| October 30, 2026 | $74.95 |
| September 30, 2026 | $65.80 |
| August 31, 2026 | $76.59 |
| July 31, 2026 | $80.09 |
| June 30, 2026 | $74.48 |
| May 29, 2026 | $66.26 |
| April 30, 2026 | $71.11 |
| March 31, 2026 | $74.26 |
| February 27, 2026 | $66.48 |
| January 30, 2026 | $77.27 |
| December 31, 2025 | $76.49 |
| November 28, 2025 | $72.01 |
| November 13, 2025 | $65.06 |
At a glance
The company
Biopharmaceutical company discovering and developing medicines for genetic diseases including ATTR cardiomyopathy, molybdenum cofactor deficiency, achondroplasia, and other rare conditions
Latest results
Quarter to September 30, 2026 · EPS -$0.42 (estimate -$0.56)
TickerLandia's take on BridgeBio Pharma
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−16.18% from the 52-week high
Analysts · 22 analysts
Average target$106.85+36.46% vs. price
Buy 19 · Hold 3 · Sell 0 · Strong buy
TickerLandia Fingerprint: BridgeBio Pharma
Compared with similar companies: very low earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Profitabilityaverage45
How much it earns on revenue and capital.
Metric Value Position in group Net margin −59.8% 12 ROA −14.0% 18 Operating margin −37.3% 24 ROE 32.8% 84 Gross margin 94.3% 86 Earnings stabilityvery low10
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2,696.9% 8 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Growthhigh71
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −18.57% 45 Average revenue growth (3 years) +86.30% 80 Revenue growth (year over year) +192.60% 89 Financial strengthaverage48
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −2.82 23 Debt/equitycounts in reverse: lower means more financial strength · negative shareholders' equity −1.35 99 Current ratio 2.09 22 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumaverage59
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +12.35% 67 1-year return +20.35% 61 Distance from 200-day average +7.71% 63 Relative strength (3 months) −0.56% 45 Riskaverage56
How much the price swings.
Metric Value Position in group Volatility (60 days) 35.7% 55 Maximum drawdown (12 months) 29.8% 52 Beta (1 year) 0.95 63
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
How BridgeBio Pharma is valued
Compared with 11 similar companies
| Metric | BridgeBio Pharma | Position in the group | Band |
|---|---|---|---|
| Operating margin | -37.3% | Low | |
| ROE | 32.8% | Middle | |
| Debt/equity | -1.35 | Low | |
| Net margin | -59.8% | Low | |
| Price/sales | 16.1 | High |
Grey band: the middle half of the group; tick: the median; dot: BridgeBio Pharma. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$243.68M
Latest quarter · Q2 2026
Net income
-$152.22M
Latest quarter · Q2 2026
Quarterly net margin
-62.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $15.25B
- EPS
- -$3.03
- Volume
- 1.15M
- Daily trading
- €200.16M
- Dividend yield
- 0.00%
How BridgeBio Pharma is changing
All resultsRevenue grew 127.4% a year on average over the last 5 years
Operating margin rose from −603.3% to −100.0%
Shares outstanding up 62.3% in 5 years
Returns
BridgeBio Pharma returns
$1,000 invested in BridgeBio Pharma 5 years ago, on November 15, 2021, would be worth $1,626 today: +62.58% in total, +10.22% per year. This is the price return only: dividends are excluded.
| Period | BridgeBio Pharma | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +23.70% | −3.12% | $1,237 |
| 6 months | +14.12% | +1.58% | $1,141 |
| Year to date | +2.37% | +10.46% | $1,024 |
| 1 year | +20.35% | +12.23% | $1,204 |
| 3 years | +184.52% | +71.41% | $2,845 |
| 5 years | +62.58% | +61.48% | $1,626 |
Over the last 6 months it has done better than 45% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
BridgeBio Pharma: technical analysis
BridgeBio Pharma shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 13.2% below its all-time closing high ($90.17, July 9, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 65
- Between 30 and 70
- vs 200-session average
- +7.71%
Support and resistance
Price areas where BridgeBio Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$85.42+9.09%4 touches, last on August 19, 2026
- Resistance$79.06+0.97%8 touches, last on August 17, 2026
- Last price$78.30
- Support$70.21−10.33%5 touches, last on September 23, 2026
- Support$68.13−12.99%2 touches, last on October 2, 2026
- Support$64.98−17.02%2 touches, last on September 28, 2026
Volatility and risk
Over the last year it has moved roughly in line with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.95
- Volatility (60 sessions, annualised)
- 35.7%
- Largest fall in the last year
- −29.80%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
BridgeBio Pharma: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for BridgeBio Pharma has been June: +14.48% on average, positive in 6 years out of 7. The weakest has been April: −6.82% on average, positive in 2 years out of 7. November, the current month, has been positive in 5 years out of 7 (+10.28% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −4.31% | −1.60% | 3 of 7 |
| February | +0.96% | −0.41% | 3 of 7 |
| March | +7.82% | −0.95% | 3 of 7 |
| April | −6.82% | −9.22% | 2 of 7 |
| May | −3.80% | −5.51% | 2 of 7 |
| June | +14.48% | +12.41% | 6 of 7 |
| July | +12.65% | +4.99% | 5 of 8 |
| August | +2.86% | +4.98% | 5 of 8 |
| September | −6.23% | −7.52% | 2 of 8 |
| October | +5.39% | +5.12% | 6 of 8 |
| November | +10.28% | +14.96% | 5 of 7 |
| December | +4.72% | +6.22% | 5 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
BridgeBio Pharma and its competitors
With 1,081 employees and revenue of 502.1 million USD in the fiscal year ended December 2025, BridgeBio Pharma discovers, develops and delivers medicines for patients with genetic diseases. Its offerings include Attruby, an oral treatment for cardiomyopathy linked to wild-type or transthyretin-mediated amyloidosis, and NULIBRY, an intravenous form of fosdenopterin for molybdenum cofactor deficiency. Late-stage candidates target achondroplasia and hypochondroplasia with low-dose infigratinib, hypocalcemia and hypoparathyroidism with encaleret, and LGMD2I with BBP-418, while the gene therapy BBP-812 addresses Canavan disease.
- Headquarters
- Palo Alto, United States
- Employees
- 1,081
- Founded
- 2015
- Chief executive
- Neil Kumar
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| BridgeBio PharmaBBIO | $15.25B | -37.3% | — | +14.12% |
| Jazz PharmaceuticalsJAZZ | $15.5B | 27.4% | 71.5 | +3.97% |
| ExelixisEXEL | $16.84B | 40.2% | 20.7 | +34.53% |
| Ascendis PharmaASND | $18.06B | 30.9% | 18.1 | +13.06% |
| Bio-TechneTECH | $11.44B | 21.7% | 66.8 | +62.17% |
| Halozyme TherapeuticsHALO | $11.43B | 56.7% | 25.1 | +43.18% |
Same industry or related industries, similar size. Compare BridgeBio Pharma with its competitors · Full profile
